EXEL — Exelixis, Inc.
$69.00
$-0.84 (-1.20%)
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Market Cap
$16.84B
Forward P/E
16.1x
52-Week Range
N/A
EXEL Price History
Revenue vs. Net Income
$2.3B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$844M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
31.4%
ROCE · FY2025 (approx.)
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
4.2x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
1.7%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-4.8%
Net buyback · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
